Phase 2Not yet recruitingAge-related condition
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
A Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Trial: The Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Low-dose Tamibarotene on Improving NT-proBNP in Patients With Heart Failure With Preserved Ejection Fraction (RELIEF Trial)
- Sponsor
- Nagoya University (Academic or other)
- Enrolment
- 90 planned
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Tamibarotene; Placebo
- Ages
- adults, older adults
- Registry
- NCT07855692
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF).
Primary outcomes
- Change From Baseline in serum NT-proBNP
History
Study completion expected
Primary completion expected
Registered
Started